Biotherapeutics Discovery. Simplified.
From mRNAs and therapeutic proteins to antibodies, bi-specifics, ADCs and engineered therapeutic cell lines such as TCRs and CAR-T cells, integrating and managing these modalities remains a challenge. How can you simplify and accelerate the design, monitoring, testing, tracking, and evaluation of novel biotherapeutics in any format, while ensuring you’re also prepared for an AI-driven future?
This is where Genedata comes in.
Our Customers
- Get the Most Out of Discovery Data.
- Establish Data Connectivity. From Day One.
- Automate. Go High-Throughput.
- Better Outcomes. Integrate AI/ML.
Get the Most Out of Discovery Data.
- Integrate scientific insights and utilize interactive visualizations to better identify and validate new drug targets and streamline antigen production.
- Register all biotherapeutic modalities including molecules, molecule components, and their DNA, RNA, and amino acid sequences across the entire discovery process to ensure data uniqueness.
- Design molecules in any format without the need to copy/paste sequences and automatically create and register vectors in bulk.
- Efficiently clone in silico, manage clone libraries, and track plate operations. Systematically annotate and organize tens of thousands of different DNA sequences.
- Leverage in silico prediction together with experimental data to select the best hits and minimize wet lab experiments.
Establish Data Connectivity. From Day One.
- Centralize assay analysis and integrate and visualize clone assay results and benefit from specialized tools for multi-parametric optimization.
- Track complete history and parentage of every clone, batch, and sample across every step of the discovery workflow.
- Capture all screening data using standardized formats and protocols to ensure data consistency and compatibility, extract the most value, and drive innovation.
- Connect internal and external teams, sites, and processes for real-time access to all data.
- Ensure data quality, data consistency, and version control at every step.
Automate. Go High-Throughput.
- Automate screening and optimization processes through scalable software and modular architecture that can handle largest data volumes.
- Streamline management of biological data such as sequence alignment, structural modelling, large-scale data analysis, and reporting.
- Integrate instruments, robotics, and automated data capture and analysis for routine tasks as well as complex experimental sequences.
- Automatically execute workflows, track progress, and manage dependencies.
- Monitor both historical and real-time assay results by comparing performance across plates, reference and repeated samples, and analysis sessions.
Better Outcomes. Integrate AI/ML.
- Simplify access to multi-source data and facilitate integrative analyses with a diverse range of analytical solutions.
- Avoid data duplication using two-way integration with laboratory information management systems (LIMS), electronic lab notebooks (ELNs), and other platforms.
- Integrate in silico predictions with experimental results to improve probability of success and shorten project timelines.
- Identify the best-performing candidates for a given target or indication sooner.
- Leverage a structured data foundation for AI/ML to drive innovation and guide future discovery projects.
Customer Stories
Automating MS Analysis of Oligo Biotransformations
“The automated workflow accelerates data processing, eliminates manual tasks, and reduces delivery time from weeks to days, allowing focus on key business tasks.” Katharina Root, Novartis.
Digitalization & Automation for Biotherapeutic Discovery
Discover how Merck transforms biotherapeutic discovery by digitalizing and automating R&D workflows with Genedata Biologics, enhancing efficiency, data integration, and decision-making for mAbs, Bispecifics, and ADCs.
Pfizer Centralizes Global R&D Data to Enhance Collaboration
“Pfizer is thrilled to fully access this system for antibody discovery and protein engineering, now integral to our large-molecule discovery engine.” Will Somers, Ph.D., VP Global Biotherapeutic Technologies, Pfizer.